Association of Adiponectin rs1501299 and rs266729 Gene Polymorphisms With Nonalcoholic Fatty Liver Disease

Hashemi, Mohammad; Bojd, H Hanafi; Eskandari-Nasab, Ebrahim; Bahari, Ali; Hashemzehi, Noor Allah; Shafieipour, Sara; Narouie, Behzad; Taheri, Mohsen; Ghavami, Saeid

doi:10.5812/hepatmon.9527

Cited by 66 publications

(50 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ethical approval for the study was obtained from the Ethics Committee of Zahedan University of Medical Sciences, and written informed consent was obtained from all participating patients. Blood samples were collected in EDTA-containing tubes from patients and controls, and DNA was extracted using the salting out method as previously described (30).…”

Section: Methodsmentioning

confidence: 99%

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Abstract. Tumor protein 53 (TP53), a tumor suppressor gene, is a vital cellular cancer suppressor in multicellular organisms. Murine double minute-2 (MDM2) is an oncoprotein that inhibits TP53 activity. A number of studies have examined the association of TP53 and MDM2 polymorphisms with the risk of common forms of cancer, but the findings remain inconclusive. The present study aimed to evaluate the impact of the 40-bp insertion/deletion (I/D) polymorphism (rs3730485) in the MDM2 promoter region and the 16-bp I/D polymorphism (rs17878362) in TP53 on the susceptibility of prostate cancer (PCa) in a sample of the Iranian population. This case-control study included 103 patients with pathologically confirmed PCa and 142 patients with benign prostatic hyperplasia. The IntroductionProstate cancer (PCa) is the most prevalent form of cancer among males in the United States (1). In Iran, the incidence of PCa is ~9.6 cases per 100,000 individuals, with a range of 3.2-16.0 per 100,000 in various geographical settings (2,3). This is comparable with the Asia-Pacific region (9.9 per 100,000), but significantly lower than in the rest of the world (32.8 per 100,000) (4). The median age at diagnosis is ~66 years and the 5-year survival rate of patients with PCa has been estimated to be 98.9% (5).The molecular mechanisms underlying the progression and carcinogenesis of PCa have not yet been clarified. Additional molecular markers that may be employed to detect PCa and to individualize patient therapy and prognosis are of great clinical importance. A number of large cohort and case-control studies with various populations suggest that family history is a primary risk factor for PCa (6-10).In humans, the tumor protein 53 (TP53) gene is located on the short arm of chromosome 17 (17p13.1) (11). TP53, an important tumor suppressor gene, is a crucial regulator of apoptosis and the cell cycle (12-15). When it is mutated, this regulation may be lost, leading to uncontrolled cell proliferation and potentially tumorigenesis (16).The human MDM2 gene is mapped on chromosome 12q14. 3-15 (17). MDM2 functions as a key negative regulator of TP53 (18)

show abstract

Section: Methodsmentioning

confidence: 99%

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ethical approvals for recruitment were provided from the local Ethics Committee of Zahedan University of Medical Sciences, and informed consent was obtained from all patients and healthy individuals. Blood samples were collected in EDTA-containing tubes from the cases and controls, and genomic DNA was extracted using the salting out method, as described previously (34).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs or miRs) are a family of small non-coding RNAs that function as oncogenes or tumor suppressor genes. Recent evidence suggests that the pri-miR-34b/c rs4938723 variant is associated with the development of cancer. At present, there is an inconsistent association between the single-nucleotide polymorphism in pri-miR-34b/c and cancer in the limited studies. The present study is a case-control investigation, with 263 breast cancer (BC) patients and 221 control women, which examined the potential association of the pri-miR-34b/c rs4938723 polymorphisms with BC susceptibility. The polymorphisms were genotyped by the polymerase chain reaction restriction fragment length polymorphism method. No significant association between the pri-miR-34b/c rs4938723 variant and BC was identified [TC vs. TT: Odds ratio (OR), 0.87; 95% confidence interval (CI), 0.60-1.26; P=0.506; CC vs. TT: OR, 1.22; 95% CI, 0.61-2.47; P= 0.600; TC+CC vs. TT: OR, 0.91; 95% CI, 0.64-1.31; P= 0.648; CC vs. TT+TC: OR, 1.32; 95% CI, 0.67-2.59; P= 0.498; C vs. T: OR, 0.99; 95% CI, 0.75-1.31; P= 0.986]. However, a significant association was observed between the pri-miR-34b/c rs4938723 genotypes and clinicopathological characteristics, such a grade, progesterone receptor and human epidermal growth factor receptor 2 status were observed (P<0.05). These findings suggest that the pri-miR-34b/c rs4938723 variant may not be a risk factor for the development of BC. IntroductionBreast cancer (BC), the most prevalent type of cancer in women, is a major public and global health problem and accounts for 14% of total annual cancer fatalities worldwide (1). Similarly, BC is the most common malignancy affecting Iranian women (2). Although the etiology of BC remains to be identified, genetic factors are shown to have important roles in the pathogenesis and progress of this malignancy (3-8).MicroRNAs (miRNAs or miRs) are a class of single-stranded non-coding RNA typically 17-25 nucleotides in length that have key roles in the regulation of cellular processes by targeting mRNAs for cleavage or translational repression (9,10). They regulate the expression of genes at the post-transcriptional level by targeting the 3' untranslated regions of mRNAs. Cumulative evidence suggests that the dysregulation of miRNA expression is involved in the tumorigenesis by acting as tumor suppressors or oncogenes (11-15). Single-nucleotide polymorphisms (SNPs) or mutations in miRNA genes can affect the miRNA biosynthesis and expression of target genes, therefore resulting in diverse functional consequences and thereby possibly representing potentially important biomarkers for the prognosis of cancer (7,(16)(17)(18).The pri-miR-34b/c gene resides in a CpG island within the intron of the B-cell translocation gene 4. Therefore, it is expected that pri-miR-34b/c is co-transcribed by either the promoter of the protein-coding gene or by its own transcription initiation region, as is the case with the majority of miRNAs, whether they are intergenic or located within the i...

show abstract

“…Ethical approval for subject and patient recruitment was obtained from the local Ethics Committee of Zahedan University of Medical Sciences (Zahedan, Iran), and informed consent was obtained from all patients and healthy individuals. Blood samples (2 ml) were collected from patients and healthy controls, stored in EDTA-containing tubes and the DNA was extracted according to the salting-out method, as described previously (25). The quality of the purified DNA was assessed by electrophoresis on 1% agarose gel (100 V for 20 min), quantitated spectrophotometrically by measuring the absorbance at 260 nm (Lambda 25; PerkinElmer, Inc., Waltham, MA, USA), and stored at -20˚C until further use.…”

Section: Methodsmentioning

confidence: 99%

FEN1 −69G>A and +4150G>T polymorphisms and breast cancer risk

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract. Flap endonuclease 1 (FEN1), a DNA repair protein, is important in preventing carcinogenesis. Two functional germ line variants -69G>A (rs174538) and +4150G>T (rs4246215) in the FEN1 gene have been associated with risk of various types of cancer. The aim of the present study was to evaluate the possible impact of FEN1 polymorphisms on risk of breast cancer (BC) in a sample of Iranian subjects. The FEN1 -69G>A and +4150G>T polymorphisms were analyzed in a case-control study that included 266 BC patients and 225 healthy females. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to genotype the variants. The findings demonstrated that the FEN1 -69G>A and +4150G>T polymorphisms were not associated with BC risk in co-dominant, dominant and recessive inheritance models. The findings indicated that GG/GT, GA/GG and GA/TT genotypes significantly decreased the risk of BC when compared with -69GG/+4150GG. Furthermore, haplotype analysis indicated that -69G/+4150T as well as -69A/+4150G significantly decreased the risk of BC compared with -69G/+4150G. Thus, these findings demonstrated that haplotypes of FEN1 -69G>A and +4150G>T polymorphisms decreased the risk of BC in an Iranian population. Further studies with larger sample sizes and different ethnicities are required to validate the present findings.

show abstract

Association of Adiponectin rs1501299 and rs266729 Gene Polymorphisms With Nonalcoholic Fatty Liver Disease

Cited by 66 publications

References 54 publications

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk

FEN1 −69G>A and +4150G>T polymorphisms and breast cancer risk

Contact Info

Product

Resources

About